4. Issues of Ethnopharmacology in HIV Management
References
American Medical Association, Critical Path Institute. Pharmacogenomics: increasing the safety and effectiveness of drug therapy. American Medical Association; Chicago, Illinois; 2011.
Owen A, Pirmohamed M, Khoo SH, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenet Genomics. 2006;16:693-703.
Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614.
Moyle GJ, Dejesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417-425.
Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther. 2003;8:36-41.
Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565-573.
Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24:1502-1514.
DHHS. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: www.aidsinfo.nih.gov/guidelines. Accessed April 3, 2012.
Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr. 2010;2:RRN1203.
Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21:41-46.
Avihingsanon A, van der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009;85:402-408.
Centers for Disease Control and Prevention. HIV and viral hepatitis. Fact sheet. Available at: www.cdc.gov/hiv/resources/factsheets/hepatitis.htm. Accessed April 4, 2012.
Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics. 2006;16:315-320.
Morello J, Cuenca L, Soriano V, et al. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis. 2010;202:1185-1191.
Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet. 2007;370:12-14.
Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30:S177-184.
Payne DA, Bryant BJ. HIV pharmacogenomics: closer to personalized therapy? Am J Pharmacogenomics. 2004;4:141-150.